New export license required for synthetic DNA sent abroad

What it does

This bill requires the U.S. government to issue export licenses for synthetic DNA and RNA sequences being sent to foreign entities tied to countries of concern (primarily China). It establishes that such genetic material—whether designed by humans or AI—cannot be exported without government approval, citing national security risks that China may use the information to advance its military and intelligence capabilities.

Why we flagged it

The bill's core mechanism is a licensing requirement for exports of synthetic DNA/RNA sequences to foreign entities of concern, framed as a national security measure to prevent intellectual property theft and military modernization by adversaries.

What the text implies

• The definition of 'foreign entity of concern' is broad and includes any foreign person 'owned, directed, or controlled by' a government entity or foreign person of a country of concern—potentially capturing U.S. subsidiaries of foreign companies or joint ventures with opaque ownership structures.
• The licensing requirement applies to 'digital sequences'—binary files representing DNA/RNA—which may capture not just physical exports but also digital transmission of genetic designs, potentially affecting academic collaboration and open-source biotech research.
• The bill references but does not restate section 734.3 of the Export Administration Regulations, creating a carve-out whose scope depends on external regulatory text not included in this bill.
• No explicit timeline or criteria for license approval/denial are stated, potentially creating uncertainty for biotech companies and researchers about what constitutes approvable export.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill restricts government power to allow exports of sensitive biotechnology information to foreign adversaries, protecting U.S. national security and preventing intellectual property theft that could enable hostile military modernization. Citizens benefit from reduced risk of biotech IP exploitation by foreign powers.

Who stands to gain

• U.S. biotechnology and synthetic biology companies (protected from IP theft)
• U.S. defense and intelligence contractors (reduced foreign access to dual-use biotech)

Named in the bill

Secretary of Commerce (licensing authority), People's Republic of China, Export Administration Regulations, Export Control Reform Act of 2018, Research and Development, Competition, and Innovation Act, Foreign entities of concern

Where it stands

11 cosponsors: 8 Republicans, 3 Democrats.

• Dec 11, 2025 — Introduced · Congress.gov: “Introduced in House”
• Dec 11, 2025 — Referred to House Committee on Foreign Affairs · Congress.gov: “Referred to the House Committee on Foreign Affairs”
• Apr 22, 2026 — Markup held in committee · Congress.gov: “Committee Consideration and Mark-up Session Held”
• Apr 22, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported in the Nature of a Substitute (Amended) by the Yeas and Nays: 30 - 14”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

7 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $11,942,500 in lobbying spend. A filing names 52 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 86% of bills with at least one filing.

Warren Davidson, the sponsor, reported $281,400 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
• Amgen Inc — $2,440,000 on 1 filing
• Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
• Lenovo (united States) Inc. — $570,000 on 1 filing
• Fdd Action — $530,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.